Arctic Vision Acquires MDCO Technology's Ophthalmic Device Business
Analysis based on 7 articles · First reported Feb 02, 2026 · Last updated Feb 02, 2026
The acquisition of MDCO Technology by Arctic Vision is expected to create an industry-leading pipeline in ophthalmic innovation, combining drug and device capabilities. This could lead to increased competition and advancements in the ophthalmology market, potentially benefiting patients and investors in the long term.
Arctic Vision, a global ophthalmic company headquartered in China===Shanghai, has announced an agreement to acquire the innovative ophthalmic device business of MDCO Technology, a China===Hangzhou-based ophthalmic medical-device company. This transaction will integrate MDCO Technology's premium intraocular lens, implantable contact lens, and refractive-device platforms into Arctic Vision's global ophthalmic innovation framework. The acquisition is a pivotal step for Arctic Vision's long-term growth strategy, expanding its pipeline with innovative therapeutics and strengthening its global ophthalmic business by combining advanced device engineering and intelligent manufacturing with existing innovation capabilities. MDCO Technology will become a wholly owned subsidiary of Arctic Vision, with key operations maintained in China===Shanghai, China===Hangzhou, and United States===California. Both Eddy Wu, CEO of Arctic Vision, and Liang Liu, Chairman of MDCO Technology, expressed positive outlooks on the merger, highlighting the creation of a comprehensive ophthalmic innovation ecosystem and accelerated market access for MDCO Technology's products.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard